Article
Medicine, Research & Experimental
Erika S. Varady, L. Angel Ayala, Pauline U. Nguyen, Vanessa M. Scarfone, Alborz Karimzadeh, Cuiwen Zhou, Xiyu Chen, Scott A. Greilach, Craig M. Walsh, Matthew A. Inlay
Summary: Donor cell conditioning with the glucocorticoid fluticasone propionate (FLU) prior to transplantation increases HSC engraftment and reduces the severity and incidence of graft-versus-host disease (GvHD) in allogeneic hosts.
EMBO MOLECULAR MEDICINE
(2023)
Article
Immunology
Thomas Krueger, Rebekka Wehner, Maik Herbig, Martin Kraeter, Michael Kramer, Jan Moritz Middeke, Friedrich Stoelzel, Catrin List, Katharina Egger-Heidrich, Raphael Teipel, Uta Oelschlaegel, Martin Wermke, Helena Jambor, Manja Wobus, Johannes Schetelig, Korinna Joehrens, Torsten Tonn, Julien Subburayalu, Marc Schmitz, Martin Bornhauser, Malte von Bonin
Summary: Functional impairment of the bone marrow niche, particularly a decrease in mesenchymal stromal cells (MSCs), is associated with cytopenia and graft failure after hematopoietic cell transplantation. Acute graft-versus-host disease (aGvHD) is shown to significantly reduce MSC numbers, and this reduction can be observed before clinical onset of aGvHD. The different phenotypic and functional characteristics of MSCs depending on the occurrence of aGvHD suggest that they may contribute to alloreactivity after transplantation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell & Tissue Engineering
Robert Puckrin, Alex Chi Fung Kwan, Nikki Blosser, Catherine Leyshon, Peter Duggan, Andrew Daly, Victor Zepeda, Douglas Stewart, Ahsan Chaudhry, Jan Storek, Kareem Jamani
Summary: Corticosteroids are not effective as GVHD prophylaxis for patients with CNI intolerance, as they may increase the risks of acute GVHD and poor outcomes.
Article
Oncology
Ana Claudia Scaraficci, Patricia Maria Fernandes, Fabio Abreu Alves, Jayr Schmidt Filho, Graziella Chagas Jaguar
Summary: The study revealed that the mean time for oral GVHD to develop after AHCT was 229 days, with pain and xerostomia being the main symptoms, and ulcers being the most common oral manifestation. Patients who received myeloablative conditioning regimen had a higher survival rate.
SUPPORTIVE CARE IN CANCER
(2022)
Review
Cell Biology
Konradin F. Muskens, Caroline A. Lindemans, Mirjam E. Belderbos
Summary: GvHD is a major complication of HCT, causing severe hematopoietic dysfunction. Immune activation during GvHD damages hematopoietic stem cells and their niche in the bone marrow, leading to reduced functionality. Complications and treatments associated with HCT exacerbate hematopoietic dysfunction.
Article
Hematology
Abu-Sayeef Mirza, Ankita Tandon, Dakota Jenneman, Shu Cao, Thomas Brimer, Ambuj Kumar, Michelle Kidd, Farhad Khimani, Rawan Faramand, Asmita Mishra, Hien Liu, Taiga Nishihori, Lia Perez, Aleksandr Lazaryan, Nelli Bejanyan, Michael Nieder, Claudio Anasetti, Joseph Pidala, Hany Elmariah
Summary: This study retrospectively analyzed the outcomes and subsequent management of patients with intolerance to the TAC/SIR regimen following allogeneic hematopoietic cell transplantation. The results showed that TAC/SIR intolerance was associated with poorer outcomes, with early intolerance contributing to a higher risk of acute graft-versus-host disease, increased nonrelapse mortality, and inferior survival. Most patients who developed intolerance were switched to alternative two-drug regimens, while those with late intolerance tended to be continued on single-drug therapy.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Letter
Oncology
Yiyin Chen, Yang Xu, Depei Wu
Summary: This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) discussed at the 2022 ASH Annual Meeting, including the use of innovative agents and regimens. Key advancements highlighted include abatacept, the first FDA-approved drug for acute GvHD prophylaxis, RGI-2001 that promotes regulatory T cell expansion, and cell therapies such as Orca-T and Orca-Q. These advancements offer promising strategies and options for GvHD prevention and may lead to improved post-transplant patient outcomes in terms of survival rates.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Sook-Kyoung Heo, Eui-Kyu Noh, Yoo Jin Lee, Yerang Shin, Youjin Kim, Hyeon-Su Im, Hyeyeong Kim, Su Jin Koh, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi
Summary: This study investigated the serum protein profiles of patients who had undergone hematopoietic cell transplantation (HCT) to identify predictive biomarkers of severe acute graft versus host disease (GVHD). The results showed that higher levels of sVCAM-1 at baseline and on day + 14 could be significant predictive biomarkers of severe aGVHD.
Article
Medicine, General & Internal
Eun Sil Kim, Yiyoung Kwon, Yon Ho Choe, Mi Jin Kim, Keon Hee Yoo
Summary: This study investigated the outcomes of gastrointestinal graft-versus-host disease (GVHD) in pediatric patients undergoing hematopoietic stem cell transplantation (HCT) according to the clinical, endoscopic, and histologic severity. The results showed that patients with higher histologic severity had earlier onset of GVHD symptoms and a higher proportion of severe clinical gastrointestinal GVHD. It highlights the importance of histologic evaluation in the diagnosis of clinical gastrointestinal GVHD.
FRONTIERS IN MEDICINE
(2023)
Article
Immunology
Ning Wu, Ruoyang Liu, Shuang Liang, Haitao Gao, Lan-Ping Xu, Xiao-Hui Zhang, Jiangying Liu, Xiao-Jun Huang
Summary: In the development of aGVHD, gamma delta T cells were found to indirectly regulate the migration of CD4 T cells to target tissues, rather than directly triggering alloreactive responses. This study suggests a potential role for gamma delta T cells in recruiting alloreactive CD4 T cells through the expression of CXCR4, providing new insights into the mechanism of aGVHD and potential therapeutic targets.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Surgery
Cecile Chague, Thomas Gautier, Ludivine Dal Zuffo, Jean-Paul Pais de Barros, Audrey Wetzel, Georges Tarris, Gaetan Pallot, Laurent Martin, Severine Valmary-Degano, Valerie Deckert, Laurent Lagrost, Etienne Daguindau, Philippe Saas
Summary: This study found that HDL deficiency leads to LPS accumulation and exacerbates aGVHD. However, administration of HDL isolated from human plasma significantly decreases the mortality and severity of aGVHD. HDL infusion also plays an important role in mitigating liver aGVHD by reducing immune infiltration and inflammation.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
Review
Infectious Diseases
Fatima Allaw, Sara F. Haddad, Johnny Zakhour, Souha S. Kanj
Summary: Cytomegalovirus (CMV) is a common infection in immunocompromised patients, especially those undergoing allo-HSCT. Recent management strategies include pre-emptive treatment with frequent CMV PCR monitoring and the use of new drugs like letermovir. Treatment of CMV disease is challenging due to drug resistance, but promising results have been seen with maribavir and other alternative treatments such as immunotherapy, artesunate, and leflunomide.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Review
Biochemistry & Molecular Biology
Riccardo Masetti, Daniele Zama, Davide Leardini, Edoardo Muratore, Silvia Turroni, Patrizia Brigidi, Andrea Pession
Summary: The gut microbiome plays a significant role in hematopoietic stem cell transplantation, with its metabolites mediating interactions between intestinal microbial communities and the host. New data offer a fresh perspective on the role of microbiome-derived metabolites in transplant settings.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Yosuke Okada, Hideki Nakasone, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Shimpei Matsumi, Ayumi Gomyo, Aki Tanihara, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Shun-Ichi Kimura, Shinichi Kako, Noriko Oyama-Manabe, Yoshinobu Kanda
Summary: Pancreatic atrophy is associated with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. The recovery of pancreatic thickness plays a crucial role in body weight recovery, but pancreatic atrophy may have a negative impact on prognosis.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Oncology
Zhao Wang, Sudong Zhang, Xiaoyu Zhang, Li Liu, Lukun Zhou, Yuyan Shen, Rongli Zhang, Yi He, Donglin Yang, Erlie Jiang, Xiaoming Feng, Jiaxi Zhou, Tao Cheng, Mingzhe Han, Sizhou Feng
Summary: This study shows that both graft MAIT cells and peripheral blood MAIT cells are closely related to the development of aGVHD post allogeneic HCT. The interferon-alpha response pathway may be a critical regulatory mechanism for the involvement of MAIT cells in aGVHD development.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Audrey Grain, Fanny Rialland-Battisti, Patrice Chevallier, Nicolas Blin, Jean-Hugues Dalle, Gerard Michel, Nathalie Dhedin, Regis Peffault de Latour, Cecile Pochon, Ibrahim Yakoub-Agha, Yves Bertrand, Anne Sirvent, Charlotte Jubert, Edouard Forcade, Ana Berceanu, Virginie Gandemer, Pascale Schneider, Jacques-Olivier Bay, Pierre-Simon Rohrlich, Eolia Brissot, Catherine Paillard, Dominique Plantaz, Stephanie Nguyen Quoc, Fanny Gonzales, Natacha Maillard, Lucie Planche, Andre Baruchel
Summary: This study compared the outcomes of children and young adults after hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL). It found that young adults had lower overall survival and graft-versus-host disease (GvHD)-free survival rates, along with higher treatment-related mortality. The higher incidence of chronic GvHD appeared to be the primary factor contributing to the worse outcomes in young adults.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
David Beauvais, Cristina Castilla-Llorente, Elisa Diral, Anne Sirvent, Audrey Vandewiele, Andre Baruchel, Ibrahim Yakoub-Agha, Karima Yakouben
Summary: The role of allogeneic hematopoietic cell transplantation (allo-HCT) after CAR T-cell therapy in hematologic malignancies is currently debated. Prolonged remissions after CAR T-cell therapy suggest a curative effect, but allo-HCT was previously the only curative treatment in relapse situations. This workshop aims to review existing data on allo-HCT after CAR T-cell therapy and propose considering allograft in selected patients with B-acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).
BULLETIN DU CANCER
(2023)
Article
Oncology
Edouard Forcade, Solenn Bacquet, Caroline Ballot, Lucille Capin, Federico Garnier, Christine Giraud, Marie-Agnes Guerout-Verite, Catherine Letellier, Alessandra Magnani, Anne-Claire Mamez, Justine Nasone, Mahamadou Sinayoko, Etienne Baudoux, Valerie Mialou, Ibrahim Yakoub-Agha, Boris Calmels
Summary: The COVID-19 pandemic disrupted allogeneic stem cell transplantation activities globally, necessitating the cryopreservation of allografts to ensure the procedure's success. Cryopreservation has been widely adopted by French speaking centers, and data from 24 centers were analyzed to assess its impact on allograft quality. The analysis clearly shows that prolonged transit time (over 48 hours) negatively affects CD34' recovery, justifying the slight increase in the requested CD34' cell dose and the importance of quality control for the infused product.
BULLETIN DU CANCER
(2023)
Article
Hematology
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Peter Remenyi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kroeger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha
Summary: With the introduction of TKI, the number of allo-HCT for CP CML patients has decreased significantly. The use of 1, 2, or 3 TKI prior to allo-HCT does not affect the overall survival, progression-free survival, relapse incidence, or non-relapse mortality. However, the disease stage and KPS score significantly influence the survival and progression-free survival, emphasizing the importance of careful candidate selection and performing allo-HCT during CP1 phase.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Biophysics
Paul Chauvet, Annalisa Paviglianiti, Myriam Labopin, Helene Labussiere, Nicolas Boissel, Marie Robin, Natacha Maillard, Marie Ouachee-Chardin, Edouard Forcade, Xavier Poire, Sylvain Chantepie, Anne Huynh, Claude Eric Bulabois, Mathieu Leclerc, Sebastien Maury, Patrice Chevallier, Thomas Cluzeau, Jean-Baptiste Mear, Jerome Cornillon, Karin Bilger, Celestine Simand, Yves Beguin, Marie-Therese Rubio, Ibrahim Yakoub-Agha, Eolia Brissot
Summary: This study compared the efficacy and safety of blinatumomab with donor lymphocyte infusion (DLI) versus blinatumomab alone in relapsed B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic stem cell transplantation (allo-HCT). The results showed that adding DLI to blinatumomab treatment did not improve outcomes in B-ALL patients who relapsed after allo-HCT.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Valerie Coiteux, Laurene Fenwarth, Nicolas Duployez, Malika Ainaoui, Cecile Borel, Alice Polomeni, Ibrahim Yakoub-Agha, Yves Chalandon
Summary: The advancement of new technologies has increased the ability to identify genetic predispositions to myelodysplastic syndromes and acute leukemias more frequently. Mutations in genes including CEBPA, RUNX1, GATA2, ETV6, and DDX41 have been found to be the most frequent and well-characterized. Early recognition of these hereditary hematological malignancies allows for better management of patients and their relatives. Allogeneic hematopoietic stem cell transplantation is often recommended for these pathologies. The type of conditioning for the transplant should be determined based on the benefit/risk assessment and the limited experience with secondary cancers in the long-term. A multidisciplinary approach is crucial in the diagnosis and treatment of these diseases.
BULLETIN DU CANCER
(2023)
Article
Hematology
Charles Guisnel, Luciane Schirmer, Stephane Morisset, Marie Robin, Helene Labussiere-Wallet, Remy Dulery, Patrice Ceballos, Edouard Forcade, Stephanie Nguyen-Quoc, Xavier Poire, Johan Maertens, Sylvain Chantepie, Patrice Chevallier, Etienne Daguindau, Alban Villate, Amandine Charbonnier, Cristina Castilla-Llorente, Nathalie Contentin, Anne Huynh, Ibrahim Yakoub-Agha, Claude-Eric Bulabois, Marie-Therese Rubio, Maud D'Aveni
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best treatment option for high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, relapse risk remains significant due to escape mechanisms from alloreactive T cells. The effectiveness of prophylactic donor lymphocyte infusions (proDLI) in preventing relapse is still debated.
ACTA HAEMATOLOGICA
(2023)
Article
Hematology
Guillermo Orti, Luuk Gras, Nienke Zinger, Maria Chiara Finazzi, Katja Sockel, Marie Robin, Edouard Forcade, Daniele Avenoso, Nicolaus Kroeger, Juergen Finke, Aleksandar Radujkovic, Mathilde Hunault-Berger, Wilfried Schroyens, Tsila Zuckerman, Jean Henri Bourhis, Yves Chalandon, Adrian Bloor, Rik Schots, Liesbeth C. de Wreede, Joana Drozd-Sokolowska, Kavita Raj, Nicola Polverelli, Tomasz Czerw, Juan Carlos Hernandez-Boluda, Donal McLornan, Ibrahim Yakoub-Agha
Summary: Allogeneic hematopoietic cell transplant (allo-HCT) is the only potential route to long-term remission for patients with blast phase transformation of myeloproliferative neoplasm (BP-MPN). A large retrospective registry-based study showed that the 3-year overall survival (OS) of BP-MPN patients undergoing allo-HCT was 36%. Factors associated with lower OS included Karnofsky Performance Score < 90 and active disease at allo-HCT, while more recent allo-HCT was associated with higher OS.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Hematology
Mathilde Sourisseau, Emmanuel Faure, Helene Behal, Paul Chauvet, Micha Srour, Antoine Capes, Valerie Coiteux, Leonardo Magro, Serge Alfandari, Enagnon Kazali Alidjinou, Nicolas Simon, Fanny Vuotto, Micheline Karam, Karine Faure, Ibrahim Yakoub-Agha, David Beauvais
Summary: Letermovir is an effective drug for CMV infection prophylaxis in adult patients undergoing allo-HCT. A risk-based strategy allows high-risk patients to benefit from letermovir while some low-risk patients can avoid its use.
Article
Biophysics
Arnon Nagler, Myriam Labopin, Stephan Mielke, Jakob Passweg, Didier Blaise, Tobias Gedde-Dahl, Jan J. J. Cornelissen, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Peter Remenyi, Gerard Socie, Gwendolyn van Gorkom, Helene Labussiere-Wallet, Xiao-Jun Huang, Marie Therese Rubio, Jenny Byrne, Charles Craddock, Laimonas Griskevicius, Fabio Ciceri, Mohamad Mohty
Summary: This study compared the outcomes of hematopoietic stem cell transplants in acute myeloid leukemia patients in first complete remission from different donor sources. The results showed that acute graft-versus-host disease (GVHD) was more common in all non-sibling donor groups. Chronic GVHD rates were also higher in certain unrelated donor groups. However, overall survival and leukemia-free survival did not differ significantly between donor types.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Arnon Nagler, Myriam Labopin, Ryszard Swoboda, Alexander Kulagin, Helene Labussiere-Wallet, Montserrat Rovira, Didier Blaise, Jan Vydra, Ibrahim Yakoub-Agha, Goda Choi, Peter Remenyi, Yener Koc, Jaime Sanz, Fabio Ciceri, Mohamad Mohty
Summary: Retrospective evaluation of transplant outcomes in adult AML patients undergoing allo-HCT in CR2 showed that post-transplant cyclophosphamide is an effective method for GVHD prophylaxis.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Hematology
Nicolas Gazeau, Suman Mitra, Morgane Nudel, Remi Tilmont, Paul Chauvet, Micha Srour, Anne-Sophie Moreau, Pauline Varlet, Enagnon Kazali Alidjinou, Salomon Manier, Franck Morschhauser, Myriam Labalette, Ibrahim Yakoub-Agha, David Beauvais
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Didier Blaise, Sergey Bondarenko, Jan Vydra, Goda Choi, Montserrat Rovira, Peter Remenyi, Ellen Meijer, Claude Eric Bulabois, J. L. Diez-Martin, Ibrahim Yakoub-Agha, Eolia Brissot, Alexandros Spyridonidis, Jaime Sanz, Amit Patel, Mutlu Arat, Ali Bazarbachi, Gesine Bug, Bipin N. Savani, Sebastian Giebel, Fabio Ciceri, Mohamad Mohty
Summary: In this study, the impact of measurable residual disease (MRD) on the outcomes of post-transplant cyclophosphamide (PTCy)-based allo-HCT in acute myeloid leukemia (AML) patients in first complete remission (CR1) was assessed. The results showed that MRD positive (MRD+) patients had higher relapse rates and lower survival rates compared to MRD negative (MRD-) patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Nico Gagelmann, Dirk-Jan Eikema, Linda Koster, Tanja Netelenbos, Andrew McDonald, Anne-Marie Stoppa, Roland Fenk, Achilles Anagnostopoulos, Gwendolyn van Gorkom, Eric Deconinck, Claude-Eric Bulabois, Michel Delforge, Donald Bunjes, William Arcese, Peter Remenyi, Maija Itala-Remes, Lorenz Thurner, Ali Zahit Bolaman, Yafour Nabil, Johan Lund, Helene Labussiere-Wallet, Patrick J. Hayden, Meral Beksac, Stefan Schoenland, Ibrahim Yakoub-Agha
Summary: This study investigated the impact of extramedullary disease (EMD) in patients with multiple myeloma (MM) after autograft and maintenance therapy. It was found that organ involvement was a significant risk factor for worse outcome. Thalidomide had no significant effect on disease progression during maintenance therapy, while lenalidomide and bortezomib improved patients' survival specifically in EMD.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Letter
Hematology
Marie Robin, Liesbeth C. de Wreede, Thomas Schroeder, Friedrich Stoelzel, Nicolaus Kroeger, Linda Koster, Uwe Platzbecker, Juergen Finke, Arnold Ganser, Didier Blaise, Fabio Ciceri, Johan Maertens, Helene Labussiere Wallet, Junfeng Wang, Patrice Chevallier, Jakob Passweg, Jan J. Cornelissen, Stephanie Nguyen, Edouard Forcade, Amandine Charbonnier, Francesca Bonifazi, Patrick Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha